Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stocks in play: Cardiol Therapeutics Inc. Baystreet - Tue Apr 28, 9:14AM CDT

Today announced the continued expansion of its pivotal Phase III MAVERIC trial in the United States, ...

CRDL.TO : 1.79 (-3.76%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program PR Newswire - Tue Apr 28, 6:27AM CDT

TORONTO , April 28, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory and...

CRDL.TO : 1.79 (-3.76%)
CRDL : 1.3100 (-4.38%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program PR Newswire - Tue Apr 28, 6:27AM CDT

TORONTO , April 28, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.79 (-3.76%)
CRDL : 1.3100 (-4.38%)
Upcoming Meeting Dates - April 20, 2026 Newsfile - Sun Apr 19, 11:00PM CDT

Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through...

SGN.VN : 0.330 (-4.35%)
TXP.TO : 0.1700 (unch)
MAI.VN : 5.790 (-2.85%)
WVM.VN : 1.730 (-0.57%)
BRAG.TO : 2.70 (+0.75%)
BRM.VN : 3.200 (-3.03%)
BYRG.CN : 0.3650 (unch)
CPH.TO : 18.10 (-0.98%)
GAME.VN : 1.800 (+5.88%)
RSM.VN : 0.325 (-1.52%)
ESM.TO : 0.1950 (-13.33%)
IPT.VN : 0.240 (+4.35%)
Stocks in play: Cardiol Therapeutics Inc. Baystreet - Tue Apr 14, 6:46AM CDT

Announced that Cardiol's President and Chief Executive Officer David Elsley, will participate in a live ...

CRDL.TO : 1.79 (-3.76%)
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Newsfile - Tue Apr 14, 6:32AM CDT

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.79 (-3.76%)
CRDL : 1.3100 (-4.38%)
Cardiol Therapeutics Announces Year-End 2025 Update on Operations Newsfile - Wed Apr 1, 6:38AM CDT

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data...

CRDL.TO : 1.79 (-3.76%)
CRDL : 1.3100 (-4.38%)
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference Newsfile - Wed Feb 25, 6:34AM CST

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.79 (-3.76%)
CRDL : 1.3100 (-4.38%)
Stocks in play: Cardiol Therapeutics Inc. Baystreet - Tue Feb 10, 8:59AM CST

Announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal ...

CRDL.TO : 1.79 (-3.76%)
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure Newsfile - Tue Feb 10, 6:34AM CST

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.79 (-3.76%)
CRDL : 1.3100 (-4.38%)

Barchart Exclusives

Why Dan Ives Is Betting on 35% Upside for Oracle Stock: This ‘Secret Sauce’ Will Make ORCL a Key Part of the ‘AI Revolution’ Barchart - Wed Apr 29, 6:30PM CDT
Ives and his team have a price target of $225 for Oracle. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.